Compare with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CHEMCRUX ENTERPRISES vs TATVA CHINTAN PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CHEMCRUX ENTERPRISES TATVA CHINTAN PHARMA CHEMCRUX ENTERPRISES/
TATVA CHINTAN PHARMA
 
P/E (TTM) x - - - View Chart
P/BV x 4.1 33.7 12.3% View Chart
Dividend Yield % 1.8 0.0 -  

Financials

 CHEMCRUX ENTERPRISES   TATVA CHINTAN PHARMA
EQUITY SHARE DATA
    CHEMCRUX ENTERPRISES
Mar-21
TATVA CHINTAN PHARMA
Mar-21
CHEMCRUX ENTERPRISES/
TATVA CHINTAN PHARMA
5-Yr Chart
Click to enlarge
High Rs93NA-   
Low Rs20NA-   
Sales per share (Unadj.) Rs108.0149.5 72.2%  
Earnings per share (Unadj.) Rs18.126.0 69.5%  
Cash flow per share (Unadj.) Rs20.529.4 69.9%  
Dividends per share (Unadj.) Rs2.000-  
Avg Dividend yield %3.5NM- 
Book value per share (Unadj.) Rs82.782.6 100.1%  
Shares outstanding (eoy) m4.9420.09 24.6%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.50-   
Avg P/E ratio x3.10-  
P/CF ratio (eoy) x2.70-  
Price / Book Value ratio x0.70-  
Dividend payout %11.10-   
Avg Mkt Cap Rs m2790-   
No. of employees `000NANA-   
Total wages/salary Rs m40241 16.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m5333,004 17.8%  
Other income Rs m859 13.4%   
Total revenues Rs m5413,063 17.7%   
Gross profit Rs m126659 19.1%  
Depreciation Rs m1267 17.8%   
Interest Rs m144 3.3%   
Profit before tax Rs m120607 19.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3184 36.9%   
Profit after tax Rs m89523 17.1%  
Gross profit margin %23.622.0 107.6%  
Effective tax rate %25.813.9 185.9%   
Net profit margin %16.817.4 96.3%  
BALANCE SHEET DATA
Current assets Rs m2751,843 14.9%   
Current liabilities Rs m631,180 5.3%   
Net working cap to sales %39.822.1 180.5%  
Current ratio x4.41.6 281.2%  
Inventory Days Days650 18,009.4%  
Debtors Days Days22,676,002110 20,563,694.5%  
Net fixed assets Rs m2121,306 16.2%   
Share capital Rs m49201 24.6%   
"Free" reserves Rs m3591,459 24.6%   
Net worth Rs m4091,660 24.6%   
Long term debt Rs m5268 1.8%   
Total assets Rs m4873,148 15.5%  
Interest coverage x82.414.6 562.4%   
Debt to equity ratio x00.2 7.2%  
Sales to assets ratio x1.11.0 114.8%   
Return on assets %18.718.0 103.5%  
Return on equity %21.931.5 69.4%  
Return on capital %29.533.8 87.3%  
Exports to sales %19.90-   
Imports to sales %15.30-   
Exports (fob) Rs m106NA-   
Imports (cif) Rs m82NA-   
Fx inflow Rs m1060-   
Fx outflow Rs m820-   
Net fx Rs m240-   
CASH FLOW
From Operations Rs m92243 37.8%  
From Investments Rs m-82-210 38.9%  
From Financial Activity Rs m-12-88 13.8%  
Net Cashflow Rs m-2-55 3.2%  

Share Holding

Indian Promoters % 72.9 79.2 92.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 10.9 -  
FIIs % 0.0 3.5 -  
ADR/GDR % 0.0 0.0 -  
Free float % 27.1 20.8 129.9%  
Shareholders   720 89,438 0.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CHEMCRUX ENTERPRISES With:   DIC INDIA LIMITED  INEOS STYROLUTION INDIA  TATA CHEMICALS  FAIRCHEM ORGANICS  ATUL  



Today's Market

Sensex Trades Higher, Nifty Above 17,250; Power Grid, IOC & Titan Among Top Gainers(10:30 am)

Asian share markets fell in early trade today hit by worries about the Omicron coronavirus variant and a hawkish tilt at the US Federal Reserve.

Related Views on News

Tatva Chintan Makes Blockbuster Debut Doubling Investors Money (Views On News)

Jul 29, 2021

Tatva Chintan Pharma lists at 95% premium over issue price of Rs 1,083.

What Next for Devyani, Zomato, & Tatva Chintan Pharma After Stellar IPO Gains? (Views On News)

Aug 20, 2021

What's the outlook for Devyani, Zomato, and Tatva Chintan Pharma after robust listings?

Ami Organics Stock Makes Impressive Debut on Bourses. Lists at 49% Premium (Views On News)

Sep 14, 2021

Shares of Ami Organics makes a strong debut on the stock exchange. Did you bid for the IPO?

Chemplast Sanmar Makes Flat Debut as IPO Frenzy Fizzles Out (Views On News)

Aug 24, 2021

The grey market had indicated a flat listing for shares of Chemplast Sanmar ahead of its debut.

Understanding Aarti Industries' Demerger (Views On News)

Aug 20, 2021

Will the pharma unit's demerger unlock value for shareholders?

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market(Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CHEMCRUX ENTERPRISES SHARE PRICE


Dec 2, 2021 03:36 PM

TRACK CHEMCRUX ENTERPRISES

  • Track your investment in CHEMCRUX ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CHEMCRUX ENTERPRISES

CHEMCRUX ENTERPRISES 8-QTR ANALYSIS

COMPARE CHEMCRUX ENTERPRISES WITH

MARKET STATS